RxDoctor Payments Data

Sara Jones

Adult Health · Knoxville, TNNPI 1003057167

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,838in general payments, 2019–2025

Across 387 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$706
  • E.r. Squibb & Sons, L.L.C.$366
  • AstraZeneca$357
  • Sanofi$295
  • Bristol Myers Squibb$294
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$901%
  • Food & beverage$7,73299%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis54$1,067
Johnson & Johnson(2 entities)24$706
E.r. Squibb & Sons, L.L.C.20$366
AstraZeneca(2 entities)18$357
Sanofi14$295
Bristol Myers Squibb16$294
Amgen17$288
Pfizer16$285
Merck12$278
Astellas Pharma US Inc13$250
Genentech USA, Inc.14$249
Takeda Pharmaceuticals U.S.A., Inc.10$211
Incyte Corporation10$204
AbbVie9$198
Daiichi Sankyo Inc.9$189
Exelixis Inc.9$171
Bayer9$154
AVEO Pharmaceuticals, Inc.4$140
Rigel Pharmaceuticals, Inc.8$123
Eisai Inc.6$108
Regeneron Healthcare Solutions, Inc.5$107
Pharmacyclics LLC, An Abbvie Company7$105
Lilly USA, LLC5$98
Janssen Scientific Affairs, LLC1$90
GSK4$82
Taiho Oncology, Inc.4$80
Beone Medicines USA, Inc.3$74
Deciphera Pharmaceuticals Inc.4$73
Karyopharm Therapeutics Inc.3$66
Tersera Therapeutics LLC2$63
Myriad Genetic Laboratories, Inc.4$59
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$57
Mirati Therapeutics, Inc.2$56
Boehringer Ingelheim3$56
Ipsen Biopharmaceuticals, Inc3$51
Tempus AI, Inc2$50
Pharmacosmos Therapeutics Inc.3$46
Seagen Inc.2$44
Caris MPI, Inc.2$39
Acceleron Pharma, Inc.2$39
Cumberland Pharmaceuticals, Inc.2$38
Jazz Pharmaceuticals Inc.2$34
Array Biopharma Inc2$34
ADC Therapeutics America, Inc.2$34
Alnylam Pharmaceuticals Inc.2$33
Springworks Therapeutics, Inc.1$32
Kyowa Kirin, Inc.2$28
Servier Pharmaceuticals LLC1$26
Blueprint Medicines Corporation1$23
Macrogenics, Inc.1$23
Geron Corporation1$21
Acrotech Biopharma Inc.1$21
Sun Pharmaceutical Industries Inc.1$20
Agios Pharmaceuticals, Inc.1$20
EMD Serono, Inc.1$19
Sobi, Inc1$19
Iovance Biotherapeutics, Inc.1$19
TG Therapeutics, Inc.1$18
Gilead1$17
Beigene USA, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,838 in reported general payments places this provider in the 90th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$35,029
Medicare patients
114
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate20$450,907
XtandiEnzalutamide14$100,714
OrgovyxRelugolix17$41,878
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$580
Ondansetron OdtOndansetron23$290
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$223
Ondansetron Hcl24$216
Potassium Chloride18$177
Promethazine Hcl17$175
Triamcinolone Acetonide14$99
Prednisone21$84
Methylprednisolone12$69
Gabapentin13$56
Levothyroxine Sodium13$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$171$450,90720 claims
Astellas Pharma US IncXtandi$250$100,71414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 adult health providers in Tennessee.

Other adult health in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →